Behcet syndrome
Drug research and approvals for behcet syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 25 studies of behcet syndrome are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 25
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Gryrotonic Training in Behcet-diseased Elders With Breast CancerNCT07929116 · Not applicable · Cairo University · starts Nov 30, 2026
- Diet Restiction in Subjects With Behcet Disease and Complaint of TinnitusNCT07702149 · Not applicable · Cairo University · starts Jun 4, 2026
- Efficacy of Physical Activity Program in Metabolic-syndrome Females With Behcet DiseaseNCT07702123 · Not applicable · Cairo University · starts Jun 2, 2026
- Behcet Disease Patients With Pulmonary Endoarterectomy: Outcomes of Program of Inspiratory Msucle TrianingNCT07662603 · Not applicable · Cairo University · starts May 6, 2026
- Clinical, Biochemical and Epigenetic Profile of Pediatric Behçet DiseaseNCT07375940 · Not applicable · Meyer Children's Hospital IRCCS · starts Jan 12, 2026
- Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy…NCT07276087 · Not reported · ÖZLEM NUR TOK YAMAN · starts Sep 11, 2025
- Ustekinumab in BEhçet's Syndrome STudyNCT07244614 · Not reported · Groupe français d'étude des Maladies Inflammatoires de loeil · starts Sep 1, 2025
- EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular DiseasesNCT07077304 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Nov 19, 2025
- Quantification & Classification of Inflammatory Cells in Uveitis Using OCTNCT07065747 · Not reported · Oregon Health and Science University · starts Sep 1, 2024
Approved 1
- ApremilastPhosphodiesterase 4 inhibitor
Phase 3 7
- InfliximabTNF-alpha inhibitor
- CyclophosphamideDNA inhibitor
- GevokizumabInterleukin-1 beta negative allosteric modulator
- CyclosporineCyclophilin A modulator
- Interferon alfa-2aInterferon alpha/beta receptor agonist
- AdalimumabTNF-alpha inhibitor
- SecukinumabInterleukin 17A inhibitor
Phase 2 10
- ColchicineTubulin inhibitor
- PentoxifyllineAdenosine A2 receptor antagonist
- AldesleukinInterleukin-2 receptor agonist
- RituximabB-lymphocyte antigen CD20 binding agent
- TocilizumabInterleukin-6 receptor alpha subunit inhibitor
- CanakinumabInterleukin-1 beta inhibitor
- UstekinumabInterleukin-12 inhibitor
- GSK-1070806Interleukin-18 inhibitor
- Dusquetide
- Mufemilast
Phase 1 or earlier 1
- AbataceptT-lymphocyte activation antigen CD86 inhibitor
How its trials ended
116 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 19 whose ending is known, 42% met their primary endpoint, 11% missed it and 47% stopped early.
- Completed, result not reported4438%
- Ongoing3429%
- Status unknown1916%
- Met its primary endpoint87%
- Stopped: other or unclear43%
- Stopped: enrollment or feasibility33%
- Missed its primary endpoint22%
- Stopped: lack of efficacy11%
- Stopped: sponsor or business decision11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA